Baetz, T., Belch, A., Couban, S., Imrie, K., Yau, J., Myers, R., Ding, K., Paul, N., Shepherd, L., Iglesias, J., Meyer, R., & Crump, M. (2003). Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: A phase II study by the National Cancer Institute of Canada Clinical Trials Group. Annals of Oncology, 14(12), 1762-1767. https://doi.org/10.1093/annonc/mdg496
Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: A phase II study by the National Cancer Institute of Canada Clinical Trials Group. / Baetz, T.; Belch, A.
; Couban, S. et al.
In:
Annals of Oncology, Vol. 14, No. 12, 12.2003, p. 1762-1767.
Research output: Contribution to journal › Article › peer-review
Baetz, T, Belch, A, Couban, S, Imrie, K, Yau, J, Myers, R, Ding, K, Paul, N, Shepherd, L, Iglesias, J, Meyer, R & Crump, M 2003, 'Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: A phase II study by the National Cancer Institute of Canada Clinical Trials Group', Annals of Oncology, vol. 14, no. 12, pp. 1762-1767. https://doi.org/10.1093/annonc/mdg496
Baetz T, Belch A, Couban S, Imrie K, Yau J, Myers R et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: A phase II study by the National Cancer Institute of Canada Clinical Trials Group. Annals of Oncology. 2003 Dec;14(12):1762-1767. doi: 10.1093/annonc/mdg496
Baetz, T. ; Belch, A. ; Couban, S. et al. / Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease : A phase II study by the National Cancer Institute of Canada Clinical Trials Group. In: Annals of Oncology. 2003 ; Vol. 14, No. 12. pp. 1762-1767.
@article{6fd76e355fe14a5fafbccbaa4773cbbd,
title = "Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: A phase II study by the National Cancer Institute of Canada Clinical Trials Group",
keywords = "Gemcitabine, Hodgkin's disease, Salvage chemotherapy",
author = "T. Baetz and A. Belch and S. Couban and K. Imrie and J. Yau and R. Myers and K. Ding and N. Paul and L. Shepherd and J. Iglesias and R. Meyer and Michael Crump",
year = "2003",
month = dec,
doi = "10.1093/annonc/mdg496",
language = "English",
volume = "14",
pages = "1762--1767",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "12",
}
TY - JOUR
T1 - Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease
T2 - A phase II study by the National Cancer Institute of Canada Clinical Trials Group
AU - Baetz, T.
AU - Belch, A.
AU - Couban, S.
AU - Imrie, K.
AU - Yau, J.
AU - Myers, R.
AU - Ding, K.
AU - Paul, N.
AU - Shepherd, L.
AU - Iglesias, J.
AU - Meyer, R.
AU - Crump, Michael
PY - 2003/12
Y1 - 2003/12
KW - Gemcitabine
KW - Hodgkin's disease
KW - Salvage chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=9144246449&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=9144246449&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdg496
DO - 10.1093/annonc/mdg496
M3 - Article
C2 - 14630682
AN - SCOPUS:9144246449
SN - 0923-7534
VL - 14
SP - 1762
EP - 1767
JO - Annals of Oncology
JF - Annals of Oncology
IS - 12
ER -
